연구동향 분석
박사

(The) therapeutic effects of BTK inhibitor in autoimmune diseases

김유연 2019년

논문상세정보
인용/피인용
' (The) therapeutic effects of BTK inhibitor in autoimmune diseases' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Bruton’s tyrosine kinase
  • HM71224
  • Lupus nephritis (LN)
  • Rheumatoid arthritis (RA)
  • Systemic lupus erythematosus(SLE)
  • b cells
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
22 0

0.0%

' (The) therapeutic effects of BTK inhibitor in autoimmune diseases' 의 참고문헌

  • Z′-LYTE™ KINASE ASSAY KIT - TYR 1 PEPTIDE PROTOCOL, accessed September 24, 2018, https://www.thermofisher.com/order/ catalog/product/PV3190.
  • Yoo, T.J., Kim, S.Y., & Stuart, J.M., et al. (1988). Induction of arthritis in monkeys by immunization with type II collagen. Journal of Experimental Medicine. 168, 777-782.
  • Y.W. Song, & E.H. Kang. (2010). Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. An International Journal of Medicine. 103(3), 139–146.
  • Xu, S., Tan, J.E., & Wong, E.P., et al. (2000). B cell development and activation defects resulting in xid like immunodeficiency in BLNK/SLP-65-deficient mice.InternationalImmunology.12, 397-404.
  • Xu, D., Kim, Y., & Postelnek, J., et al. (2012). RN486, a selective Broton’s tyrosine kinas inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. Journal of Pharmacology and Experimental Therapeutics. 341(1), 90-103.
  • Wooley, P.H., Luthra, H.S., Stewart, J., & David, C.S. (1981). Collagen arthritis in mice a MHC linked disease. Federation Proceedings. 40, 971.
  • Weintraub, J.P., Godfrey, Y., & Wolthusen, P.A. (1998). Immunological and pathological consequences of mutations in both Fas and Fas ligand. Cellular Immunology. 186, 8-17.
  • Watanabe, D., Hashimoto, S., & Ishiai, M., et al. (2001). Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. Journal of Biological Chemistry. 276(42), 38595-38601.
  • Wang, W., Rangel-Moreno, J., & Owen, T., et al. (2014). Long-Term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. The Journal of Immunology. 192, 3011-3020.
  • Wallace, D.J., Kalunian, K., & Petri, M.A., et al. (2014b). Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phaseIIb, randomised, double-blind, placebo-controlled, multicenter study. Annals of the Rheumatic Diseases. 73(1), 183-190.
  • Wallace, D.J., Gordon, C., & Strand, V. (2013a). Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow up. Rheumatology. 52(7), 1313–1322.
  • Trentham, D.E., Townes, A.S., & Kang, A.H. (1977). Autoimmunity to type II collagen: an experimental model of arthritis. Journal of Experimental Medicine. 146, 857-68.
  • Tim, Y.T.L., Kristine, P.N.G., & Geraldine, C., et al. (2009). A respective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis &Rheumatology. 61, 482- 487.
  • Thomas, J.O., & Stacie, A.D. (2003). Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Research & Therapy. 5(4), S7
  • Takemura, S., Klimiuk, P.A., & Braun, A., et al. (2001). T cell activation in rheumatoid synovium is B cell dependent. The Journal of Immunology. 167(8), 4710-4718.
  • Sylvie, S., Peggy, J., & Jens, V.P., et al. (2010). A multiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Research & Therapy. 12(4), R160.
  • Svensson, L., Jirholt, J., Holmdahl, R., & Jansson, L. (1998). B celldeficient mice do not develop type II collagen-induced arthritis (CIA). Clinical & Experimental Immunology. 111(3), 521–526.
  • Suurmond, J., & Diamond, B. (2015). Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. The Journal of Clinical Investigation. 125(6), 2194-1102.
  • Smith, C.I., Baskin, B., & Humire-Greiff, P., et al. (1994). Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down regulated in T lymphocytes and plasma cells. The Journal of Immunology. 152, 557-565.
  • Sivadas, G., Vaishnavi, V., Vini, R., & Rajeev A. (2017). Autoimmune disorders–immunopathogenesis and potential therapies. Journal of Young Pharmacists. 9(1), 14-22.
  • Simon, F. (2018). B cells and their cytokine activities implications in human diseases. Clinical Immunology. 186, 26-31.
  • Silman, A.J., & Hochberg, M.C. (2001). Epidemiology of the rheumatic diseases. Oxford University Press. 2nd edition.
  • Shaw, T., Quan, J., & Totoritis, M. (2003). B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Annals of the Rheumatic Diseases. 62(S2), 55-59.
  • Shannon, K. O’N., Mark, J.S., & Tibor, T.G., et al. (2005). Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. The Journal of Immunology. 174(6), 3781-3788.
  • Serena, B., Barbara, V., & Roberto, C. (2014). B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers. BioMed Research International. 2014, 14.
  • Segerer, S., & Schlondorff, D. (2008). B cells and tertiary lymphoid organs in renal inflammation. Kidney International. 73, 533-537.
  • Schram, B.R., Tze, L.E., & Ramsey, L.B., et al. (2008). B cell receptor basal signaling regulates antigen induced Ig light chain rearrangements. The Journal of Immunology.180, 4728-4741.
  • Rovin, B.H., Furie, R., & Latinis, K., et al. (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus nephritis assessment with Rituximab study. Arthritis & Rheumatology. 64(4), 1215–1226.
  • Rottman, J.B., & Willis, C.R. (2010).Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Veterinary Pathology. 47, 664-676.
  • Ronnelid, J., Lysholm, J., & Engstrom-Laurent, A., et al. (1994). Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis & Rheumatology. 37, 1023-1029.
  • Rigby, R.J., Rozzo, S.J., & Boyle, J.J., et al. (2004b). New loci from New Zealand Black and New Zealand White mice on chromosomes 4 and 12 contribute to lupus-like disease in context of BALB/c. The Journal of Immunology. 172, 4609-4617.
  • Rigby, R.J., & Vyse, T.J. (2004a). Models of systemic lupus erythematosus. Drug Discovery Today Disease Models. 1, 445-449.
  • Reddy, V., Jayne, D., Close D., & Isenberg D. (2013). B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Research & Therapy. 15(S1), S2.
  • Pierre, Y., Taher E.T., & Jacques-Olivier, P., et al. (2009). B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis & Rheumatism. 60(7), 1873-1880.
  • Park, J.K., Byun, J.Y., Park, J.A., & Kim, Y.Y., et al. (2016). HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Research & Therapy. 18, 91.
  • Otten M.A., Groeneveld T.W., & Flierman R., et al. (2009). Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. The Journal of Immunology. 183, 3980-3988.
  • Nguyet-Cam, V.L., Maria, V.G., & Marxena, L.B. (2016). Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management. American Family Physician. 94(4), 284-294.
  • Myasoedova, E., Crowson, C.S., & Kremers, et al. (2010). Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis & Rheumatism. 62(6), 1576-1582.
  • Mumtax, I.M., Hoyer, B.F., & Panne, D., et al. (2012). Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. Journal of Autoimmunity. 39,180-188.
  • Moustafa, H., Caroline, D., & Paul, G. (2013). B cell-derived cytokines in disease. European Cytokine Network. 24(1), 20-26.
  • Morgan, K., Clague, R.B., & Collins, I., et al. (1989). A longitudinal study of anticollagen antibodies in patients with rheumatoid arthritis. Arthritis & Rheumatology. 32, 139-145.
  • Mina-Osorio, P., LaStant, J., & Keirstead, N., et al. (2013). Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton’s tyrosine kinase. Arthritis & Rheumatology. 65(9), 2380-2391.
  • Merrill, J.T., Neuwelt, C.M., & Wallace, D.J., et al. (2010). Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: the randomized, double-blind, phaseII/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatology. 62(1), 222–233.
  • Melissa, R.A., Micah, T.M., & Mark, V.R., et al. (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England Journal of Medicine. 349, 1526-1533.
  • Marc, D.C., & Edward, K. (2015). Rituximab for rheumatoid arthritis. Rheumatology and Therapy. 2(2), 99–111.
  • Mangla, A., Khare, A., & Vineeth, V., et al. (2004). Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood. 104(4), 1191-1197.
  • Maciej, L., & Hans-Joachim, A. (2013). The pathogenesis of lupus nephritis. Journals of the American Society of Nephrology. 24(9), 1357–1366.
  • Liu, L., Di Paolo, J., & Barbosa, J., et al. (2011). Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collageninduced arthritis and mechanism based pharmacokinetic/ pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. Journal of Pharmacology and Experimental Therapeutics. 338, 154-163.
  • Lino, A., D rner, T., Bar-Or, A., & Fillatreau, S. (2016). Cytokineproducing B cells: a translational view on their roles in human and mouse autoimmune diseases. Immunological Reviews. 269(1), 130-144.
  • Levesque, M.C., & St Clair, E.W. (2008). B cell–directed therapies for autoimmune disease and correlates of disease response and relapse. The Journal of Allergy and Clinical Immunology. 121(1), 13-21.
  • Lee, K.G., Xu, S., & Wong, E.T., et al. (2008). Bruton’s tyrosine kinase separately regulates NFκB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR-9 stimulated B cells. The Journal of Biological Chemistry. 283, 11189-11198.
  • Lech, M., & Anders. H.J. (2013). The pathogenesis of lupus nephritis. Journals of the American Society of Nephrology. 24, 1357-1366.
  • Klaus, D., Norbert, G., & Hans-Ulrich, W., et al. (2003). T-cellmediated autoimmunity. American Journal of Pathology. 163(4), 1215-1226.
  • Kil, L.P., de Bruijin, M.J., & van Nimwegen, M., et al. (2012). Btk levels set the threshold for B cell activation and negative selection of autoreactive B cells in mice. Blood. 119(16), 3744-3756.
  • Katharina, H., Ann-Katrin, C. & Rudolf, A.M. (2018). Targeting B cells and plasma cells in autoimmune diseases. Frontiers in Immunology. 9, 835.
  • Kamal, D., Moudgil, P.K., & Ernest, B. (2011). Advances in Rheumatoid Arthritis Animal Models. Current Rheumatology Reports. 13(5), 456–463.
  • Jon, W.G., & David, R.W.J. (2012). B-cell depletion in the treatment of lupus nephritis. Nature Reviews Nephrology. 8, 505-514.
  • Jimin, L., Jeewoong, S., & Hui-Jung, S., et al. (2015). Safety, Pharmacokinetics and Proof-of-Mechanism of an Oral Bruton’s Tyrosine Kinase Inhibitor HM71224 in Healthy Adult Volunteers. The 16th European League Against Rheumatism (EULAR) Annual European Congress. Poster no. THU0185.
  • Jiang, H., & Chess L. (2009). How the immune system achieves selfnonself discrimination during adaptive immunity. Advances in Immunology. 102, 95-133
  • Jeffrey, L.B. (2006). B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews Drug Discovery. 5, 564–576.
  • Jeff, A.L., & Neil, A.W. (2001). The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology. 103(4), 407-416.
  • Iain, B.M., F.R.C.P., & Georg, S. (2011). The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine. 356, 2205-2219.
  • Horowitz, D.L., & Furie, R. (2012). Belimumab is approved by the FDA: what more do we need to know to optimize decision making?. Current Rheumatology Reports. 14(4), 318-323.
  • Honigberg L.A., Smith, A.M., & Sirisawad, M., et al. (2010). The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America. 107(29), 13075-13080.
  • Hogan, J., & Appel, G.B. (2013). Update on the treatment of lupus nephritis. Current Opinion in Nephrology and Hypertension. 22(2), 224-230.
  • Heller, F., Lindenmeyer, M.T., & Cohen, C.D., et al. (2007). The contribution of B cells to renal interstitial inflammation. American Journal of Pathology. 170, 457-468.
  • Hata, D., Kawakami, Y., & Inagaki, N., et al. (1998). Involvement of Bruton’s tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. The Journal of Experimental Medicine. 187(8), 1235-1247.
  • Hasegawa, K., & Hayashi, T. (2003). Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB NZWF1 mice. Lupus. 12, 838–845.
  • Halcomb, K.E., Musuka, S., & Gutierrez, T., et al. (2008). Btk regulates localization, in vivo activation, and class switching of anti- DNA B cells. Molecular Immunology. 46(2), 233-241.
  • Gregg, J.S., & Dennis, A.C. (2003). Roles of B cells in rheumatoid arthritis. Arthritis Research & Therapy. 5(4), S1
  • Gregersen, P.K., Silver, J., & Winchester, R.J. (1987). The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis & Rheumatology. 30, 1205-1213.
  • Gillooly, K.M., Pulicicchio, C., & Pattoli, M.A., et al. (2017). Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS One. 12(7), e0181782.
  • Gillissen, G., & Pusztai-Markos, Z. (1979). Cell mediated immune regulation in autoimmunity. Allergologia et Immunopathologia. 7(2), 153-168.
  • Furukawa, F., Tanaka, H., & Sekita, K., et al. (1984). Dermatopathological studies on skin lesions of MRL mice. Archives of Dermatological Research. 276, 186-194.
  • Fozya, B. (2013). Hematological disorders in patients with systemic lupus erythematosus. The Open Rheumatology Journal. 7, 87-95.
  • Flanc, R.S., Roberts, M.A., & Strippoli, G.F., et al. (2012).Treatment for lupus nephritis. Cochrane Database of Systematic Reviews. 12, CD002922.
  • Firestein, G.S. (2003). Evolving concepts of rheumatoid arthritis. Nature. 423(6937), 356–361.
  • Faurschou, M., Dreyer, L., & Kamper, A.L., et al. (2010). Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care & Research (Hoboken). 62(6), 873-880.
  • F. Susan, W., & Li, W. (2005). B cells in autoimmune diabetes. The Review of Diabetic Studies. 2(3), 121–135.
  • Erica, K.E., Richland, T., & Sharon, A., et al. (2013). Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. Journal of Pharmacology and Experimental Therapeutics. 346(2), 219-228.
  • Elena, B., Geraldine, C., Inmaculada, T., & Maria, J.L. (2012). Longterm safety of rituximab in patients with rheumatoid arthritis. International Journal of Clinical Rheumatology. 7(4), 383–390.
  • Eggert, M., Zettl, U.K., & Neeck, G. (2010). Autoantibodies in autoimmune diseases. Current Pharmaceutical Design. 16(14), 1634- 1643.
  • Edwards. J.C., Szczepanski, L., & Szechinski, J., et al. (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine. 350(25), 2572-2581.
  • Deng, G.M., Liu, L., & Bahjat, F.R., et al. (2010). Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis & Rheumatology. 62(7), 2086-2092.
  • Deng, G.M., & Tsokos, G.C. (2015). Pathogenesis and targeted treatment of skin injury in SLE. Nature Reviews Rheumatology. 11, 663-669.
  • Darren, L.A., Ashley, M.M., Iain, B.M., & Foo, Y.L. (2009). Autoimmune disease: Rheumatoid arthritis. European Journal of Immunology. 39, 1991–2058.
  • Daniel, A., & Stephan, B. (2016). Therapeutic implications of autoantibodies in rheumatoid arthritis. Rheumatic & Musculoskeletal Disease. 2(1), e000009.
  • Daien, C.I., Gailhac, S., & Mura, T., et al. (2014). Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis & Rheumatology. 66(8), 2037-2046.
  • Courtenay, J.S., Dallman, M.J., & Dayan, A.D., et al. (1980). Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 283, 666-668.
  • Cook, A.D., Rowley, M.J., & Mackay, I.R., et al. (1996). Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis & Rheumatology. 39, 1720-1727.
  • Clynes, R., Dumitru, C., & Ravetch, J.V. (1998). Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 279, 1052-1054.
  • Claire, T., Antoine, T., & Bruno, M., et al. (2016). Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clinical Kidney Journal. 10(4), 461-469.
  • Christopher, C.G. (2007). Multistep pathogenesis of autoimmune disease. Cell. 130(1), 25-35.
  • Choi, J., Kim, S.T., & Craft, J. (2012). The pathogenesis of systemic lupus erythematosus-an update. Current Opinion in Immunology. 24(6), 651-657.
  • Chengyuan, L., Danni, T., & Xiaodong, R., et al. (2018). The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. European Journal of Medicinal Chemistry. 151, 315-326.
  • Chang, B.Y., Huang, M.M., & Francesco, M., et al. (2011). The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research & Therapy. 13(4), R115.
  • Chan, O.T., Hannum, L.G., & Haberman, A.M., et al. (1999). A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. The Journal of Experimental Medicine. 189, 1639-1648.
  • Cecile, K. (2011). T follicular helper cells and B cells. Immunity. 34, 827-828.
  • Cathcart, E.S., Hayes, K.C., & Gonnerman, W.A., et al. (1986). Experimental arthritis in a nonhuman primate. I. induction by bovine type II collagen. Laboratory Investigation. 54, 26-31.
  • Carter, L.M., Isenberg, D.A., & Ehrenstein, M.R. (2013). Elevated serum B-cell activating factor (BAFF/BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus. Arthritis & Rheumatology. 65(10), 2672-2679.
  • Cameron, J.S. (1999). Lupus nephritis. Journals of the American Society of Nephrology. 10(2), 413-424.
  • Calero, I., Nieto, J.A., & Sanz, I. (2010). B cell therapies for rheumatoid arthritis: beyond B cell depletion. Rheumatic Disease Clinics. 36(2), 325-343.
  • Borchers, A.T., Leibushor, N., & Naguwa, S.M., et al. (2012). Lupus nephritis: a critical review. Autoimmunity Reviews. 12(2), 174-194.
  • Bevra, H.H., Maureen, M., & Alan, W., et al. (2013). American college of rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care & Research. 64(6), 797-808.
  • Bertsias, G., Cervera, R., & Boumps, D.T. (2012). Eular intranet. In: Systemic lupus erythematosus: pathogenesis and clinical features. EularFppIndd. 20, 476-505.accessed September 26, 2018, https://www.eular.org/myuploaddata/files/sample%20chapter20_mod %2017.pdf
  • Bach, J.F. (2002). The effect of infections on susceptibility to autoimmune and allergic diseases. The New England Journal of Medicine. 347(12), 911-920.
  • Arbuckle, M.R., McClain, M.T., & Rubertone, M.V., et al. (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England Journal of Medicine. 349, 1526-1533.
  • Annegret, K., Percy, L., & Thomas, R. (2005). Cutaneous lupus erythematosus. In: Fukumi, F. Experimental models of lupus erythematosus. Springer. 221-238.
  • Andrew, W.C. (2014). Autoimmunity and the gut. Autoimmune Diseases. 2014, 152428.